About SpeeDx
SpeeDx is a company based in Sydney (Australia) founded in 2009 by Alison V Todd and Elisa Mokany. SpeeDx has raised $78 million across 8 funding rounds from investors including CARB-X, Platinum Asset Management and Northpond Ventures. SpeeDx offers products and services including Resistance Plus GC, Plex PCR VHS, Plex PCR RespiVirus, and Resistance Plus MG. SpeeDx operates in a competitive market with competitors including DermTech, Inflammatix, Karius, MeMed and Visby Medical, among others.
- Headquarter Sydney, Australia
- Founders Alison V Todd, Elisa Mokany
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Speedx Pty Ltd
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$78 M (USD)
in 8 rounds
-
Latest Funding Round
$26 M (USD), Series C
Feb 28, 2023
-
Investors
CARB-X
& 6 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of SpeeDx
SpeeDx offers a comprehensive portfolio of products and services, including Resistance Plus GC, Plex PCR VHS, Plex PCR RespiVirus, and Resistance Plus MG.
Detects Neisseria gonorrhoeae and ciprofloxacin susceptibility markers.
Identifies herpes and syphilis lesions through PCR technology.
Detects and differentiates multiple respiratory viruses.
Tests for Mycoplasma genitalium and macrolide resistance.
Funding Insights of SpeeDx
SpeeDx has successfully raised a total of $78M across 8 strategic funding rounds. The most recent funding activity was a Series C round of $26 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in SpeeDx
SpeeDx has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include CARB-X, Platinum Asset Management and Northpond Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in life sciences & tech sectors
|
Locked | Locked | Locked | |
|
Health technology investments are made by Tenmile in Australia.
|
Locked | Locked | Locked | |
|
Tattarang is engaged in private investments across multiple sectors.
|
Locked | Locked | Locked |
Investor details for SpeeDx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SpeeDx
Investment portfolio details for SpeeDx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - SpeeDx
Detailed financials for SpeeDx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Speedx Comparisons
Peer comparison for SpeeDx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SpeeDx
SpeeDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as DermTech, Inflammatix, Karius, MeMed and Visby Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Adhesive patch biopsies for skin cancer detection are provided.
|
|
| Locked | Locked | Locked |
Provider of diagnostic solutions for systemic infections
|
|
| Locked | Locked | Locked |
Developer of a non-invasive pathogen blood test for the detection of infectious diseases
|
|
| Locked | Locked | Locked |
Provider of machine learning based diagnostic solutions for infectious diseases
|
|
| Locked | Locked | Locked |
Portable PCR diagnostics for infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of a platform for low cost molecular testing
|
Detailed competitors of SpeeDx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Speedx
Complete news archive for SpeeDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SpeeDx
SpeeDx was founded in 2009 and raised its 1st funding round 7 years after it was founded.
SpeeDx is headquartered in Sydney, Australia. It is registered at Sydney, New South Wales, Australia.
Jeremy Stackawitz is the current CEO of SpeeDx.
SpeeDx is a funded company, having raised a total of $78M across 8 funding rounds to date.
The company was established in 2009 in Sydney, Australia, within the molecular diagnostics sector. Multiplexed qPCR assays are developed for detecting HSV-1 and -2, VZV, Syphilis, and Mycoplasma genitalium, along with associated antibiotic resistance markers. Operations center on plexZyme technology, through which target nucleic acid sequences are amplified by primers to yield amplicons. Focus is placed on infectious disease testing in clinical settings.
SpeeDx's top competitors include Visby Medical, Inflammatix and DermTech.
SpeeDx offers Resistance Plus GC, Plex PCR VHS, Plex PCR RespiVirus, and Resistance Plus MG.
SpeeDx has 7 investors. Key investors include CARB-X, Platinum Asset Management, Northpond Ventures, Tenmile, and Tattarang.